NOK 14.0
(-6.35%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 13.08 Million NOK | -21.71% |
2022 | 16.71 Million NOK | 5052.25% |
2021 | 324.41 Thousand NOK | -80.6% |
2020 | 1.67 Million NOK | -19.16% |
2019 | 2.06 Million NOK | -40.65% |
2018 | 3.48 Million NOK | 532.54% |
2017 | 551.08 Thousand NOK | -65.85% |
2016 | 1.61 Million NOK | -58.55% |
2015 | 3.89 Million NOK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 6.43 Million NOK | 1466.83% |
2024 Q1 | 410.95 Thousand NOK | -92.02% |
2023 Q3 | 2.56 Million NOK | 108.83% |
2023 Q1 | 2.61 Million NOK | -50.79% |
2023 Q4 | 5.15 Million NOK | 100.67% |
2023 FY | 13.08 Million NOK | -21.71% |
2023 Q2 | 1.22 Million NOK | -52.91% |
2022 Q4 | 5.3 Million NOK | -21.37% |
2022 Q2 | - NOK | 0.0% |
2022 FY | 16.71 Million NOK | 5052.25% |
2022 Q3 | 6.74 Million NOK | 0.0% |
2021 FY | 324.41 Thousand NOK | -80.6% |
2020 FY | 1.67 Million NOK | -19.16% |
2019 FY | 2.06 Million NOK | -40.65% |
2018 FY | 3.48 Million NOK | 532.54% |
2017 FY | 551.08 Thousand NOK | -65.85% |
2016 FY | 1.61 Million NOK | -58.55% |
2015 FY | 3.89 Million NOK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Gentian Diagnostics ASA | 136.19 Million NOK | 90.391% |
Medistim ASA | 521.1 Million NOK | 97.489% |